https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):285-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):285-942003-01-01 00:00:002003-01-01 00:00:00Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-802003-01-01 00:00:002020-06-23 09:43:48Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Oncology 2003;65 Suppl 2:76-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Oncology 2003;65 Suppl 2:76-92003-01-01 00:00:002003-01-01 00:00:00Ifosfamide with regional hyperthermia in soft-tissue sarcomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Oncology 2003;64(4):312-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Oncology 2003;64(4):312-212003-01-01 00:00:002003-01-01 00:00:00A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Curr. Top. Microbiol. Immunol. 2003;276:199-214
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Curr. Top. Microbiol. Immunol. 2003;276:199-2142003-01-01 00:00:002019-02-15 08:37:54Dendritic cell vaccination and viral infection–animal models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-12-01 / Cancer Biother. Radiopharm. 2002 Dec;17(6):601-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-12-01 / Cancer Biother. Radiopharm. 2002 Dec;17(6):601-192002-12-01 00:00:002019-02-15 08:44:50Advances in dendritic cell-based vaccine of cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-11-01 / Int J Hyperthermia 2002 Nov-Dec;18(6):506-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-11-01 / Int J Hyperthermia 2002 Nov-Dec;18(6):506-202002-11-01 00:00:002019-02-15 08:48:26Cancer immunotherapy: stress proteins and hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-10-29 / Cancer Immunol. Immunother. 2002 Dec;51(11-12):663-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-10-29 / Cancer Immunol. Immunother. 2002 Dec;51(11-12):663-82002-10-29 00:00:002019-02-15 08:53:33Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-10-01 / Clin. Exp. Immunol. 2002 Oct;130(1):107-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-10-01 / Clin. Exp. Immunol. 2002 Oct;130(1):107-142002-10-01 00:00:002019-02-15 08:37:56Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B – restoration by exogenous interleukin-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-10-01 / Transfus. Apher. Sci. 2002 Oct;27(2):183-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-10-01 / Transfus. Apher. Sci. 2002 Oct;27(2):183-62002-10-01 00:00:002002-10-01 00:00:00Dendritic cells in vaccination therapies of malignant diseases
